Revvity, Inc. (RVTY) Interest Coverage Ratio: 3.87x
The interest coverage ratio for Revvity, Inc. (RVTY) is 3.87x as of Thursday, June 18, 2026.
RVTY Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
3.87x
RVTY Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $11.07B | 3.87x | N/A | N/A | N/A |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -29.20x | 3.03x | 3.75x | 5.52x |
| Baxter International Inc. (BAX)vs › | $10.29B | -1.06x | 0.71x | 2.65x | 6.89x |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 6.83x | 6.50x | 6.73x | 9.55x |
| Solventum Corporation (SOLV)vs › | $12.97B | 6.29x | 4.55x | 4.55x | 4.55x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.04B | N/A | 393.08x | 892.58x | 554.26x |
| Align Technology, Inc. (ALGN)vs › | $13.04B | N/A | 67.41x | 66.08x | 407.22x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 4.74x | 3.27x | 5.51x | 5.84x |
| DaVita Inc. (DVA)vs › | $13.34B | 3.66x | 4.05x | 3.97x | 4.62x |
| Tempus AI, Inc. (TEM)vs › | $8.66B | -3.40x | N/A | N/A | N/A |
Financial Health Indicators
Interest Coverage
3.9x
Debt/Equity
0.48
Current Ratio
1.68
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Revvity, Inc. Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Interest Coverage Ratio FAQ
- What is the interest coverage ratio for Revvity, Inc. (RVTY)?
- The interest coverage ratio for RVTY stock is 3.87x.
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh